Protagonist Therapeutics, Inc. PTGX 深 沪
已收盘 07-02 16:00:00 美东时间
131.62
+6.450
+5.15%
华盛通- 最 高131.87
- 今 开125.89
- 成交量 70.84万股
- 最 低 125.24
- 昨 收 125.17
- 总市值 84.65亿
- 52周最高 131.87
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 50.485
- 委 比 -96.18%
- 总股本 6431.14万
- 历史最高 131.87
- 量 比 0.65
- 振 幅 5.30%
- 历史最低 4.47
- 每 手 1
- 风险率 18.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多This $300 Million Biotech May Be Deeply Mispriced: Analyst
Cantor Fitzgerald initiated coverage of Silence Therapeutics Plc (NASDAQ:SLN) with an Overweight rating, arguing that the biotech’s lead candidate divesiran could emerge as a major challenger in the polycythemia vera market, with upcoming Phase 2 data expected in August serving as a potentially tran...
06-25 02:22
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
Read Also: AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients Biopharmaceutical giant AbbVie Inc. (NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics Inc. (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion. The deal strengthens it...
06-22 21:15
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics Plc (NASDAQ:SLN) shares are up during Friday’s session. On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran. SLN Stock Catalyst: SANRECO Phase 1 Follow-Up Data Recent analyses from the Phase 1 SANRECO study show potential improvements ...
06-12 22:47
Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 European Hematology Association Congress In Sweden
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress
06-01 19:20
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $118
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $118.
05-06 20:48
财报速睇 | Protagonist Therapeutics, Inc. 2026财年Q1营收0.56亿美元，同比增长99.0%；归母净利润0.04亿美元，扭亏为盈
华盛资讯5月6日讯，Protagonist Therapeutics, Inc.公布2026财年Q1业绩，公司Q1营收0.56亿美元，同比增长99.0%，归母净利润0.04亿美元，扭亏为盈。
05-06 06:20
Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over losses of $(0.19) per
05-06 04:39
Protagonist Therapeutics Exercises Opt-Out Of Rusfertide 50:50 Profit And Loss Sharing Arrangement With Takeda, Eligible For Up To $400M In Opt-Out Payments
By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the opt-out election and a
04-28 21:11
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
